JP2019506839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506839A5 JP2019506839A5 JP2018524836A JP2018524836A JP2019506839A5 JP 2019506839 A5 JP2019506839 A5 JP 2019506839A5 JP 2018524836 A JP2018524836 A JP 2018524836A JP 2018524836 A JP2018524836 A JP 2018524836A JP 2019506839 A5 JP2019506839 A5 JP 2019506839A5
- Authority
- JP
- Japan
- Prior art keywords
- isvd
- amino acid
- seq
- acid residue
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 7
- 108010017384 Blood Proteins Proteins 0.000 claims 6
- 102000004506 Blood Proteins Human genes 0.000 claims 6
- 230000002496 gastric effect Effects 0.000 claims 6
- 230000015556 catabolic process Effects 0.000 claims 5
- 238000006731 degradation reaction Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 102000007562 Serum Albumin Human genes 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021168871A JP7357038B2 (ja) | 2015-11-12 | 2021-10-14 | 改善されたｔｎｆ結合因子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254375P | 2015-11-12 | 2015-11-12 | |
| US62/254,375 | 2015-11-12 | ||
| PCT/EP2016/077595 WO2017081320A1 (en) | 2015-11-12 | 2016-11-14 | Improved tnf binders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168871A Division JP7357038B2 (ja) | 2015-11-12 | 2021-10-14 | 改善されたｔｎｆ結合因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506839A JP2019506839A (ja) | 2019-03-14 |
| JP2019506839A5 true JP2019506839A5 (enExample) | 2019-12-12 |
| JP6962915B2 JP6962915B2 (ja) | 2021-11-10 |
Family
ID=57348648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524836A Active JP6962915B2 (ja) | 2015-11-12 | 2016-11-14 | 改善されたｔｎｆ結合因子 |
| JP2021168871A Active JP7357038B2 (ja) | 2015-11-12 | 2021-10-14 | 改善されたｔｎｆ結合因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168871A Active JP7357038B2 (ja) | 2015-11-12 | 2021-10-14 | 改善されたｔｎｆ結合因子 |
Country Status (37)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PH12022550313A1 (en) | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| NO2768984T3 (enExample) * | 2015-11-12 | 2018-06-09 | ||
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| KR20220111313A (ko) * | 2019-12-06 | 2022-08-09 | 아블린쓰 엔.브이. | TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| MX2022006880A (es) * | 2019-12-06 | 2022-07-11 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23. |
| CN112300289B (zh) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用 |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| JP2024543134A (ja) * | 2021-11-29 | 2024-11-19 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 修飾されたタンパク質又はポリペプチド |
| AU2023373192A1 (en) * | 2022-11-04 | 2025-04-17 | St. Jude Children's Research Hospital, Inc. | Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| EP4665755A1 (en) | 2023-02-17 | 2025-12-24 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1498427B1 (en) | 1992-08-21 | 2009-12-16 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| AU3295299A (en) | 1998-02-19 | 1999-09-06 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
| WO2006059108A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
| RU2464276C2 (ru) * | 2005-05-18 | 2012-10-20 | Аблинкс Н.В. | Улучшенные нанотела против фактора некроза опухоли-альфа |
| DK2444424T3 (en) | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| EP3181141A1 (en) | 2005-08-30 | 2017-06-21 | Intrexon Actobiotics NV | Anti-tnf alpha producing lactic acid bacteria for the treatment of inflammatory bowel disease |
| CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| CN101454344A (zh) | 2005-12-01 | 2009-06-10 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的非竞争性域抗体形式 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| AU2008252853B2 (en) | 2007-05-24 | 2011-12-01 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| EP2398827A2 (en) * | 2009-02-19 | 2011-12-28 | Glaxo Group Limited | Improved anti-tnfr1 polypeptides, antibody variable domains&antagonists |
| AU2010233658B2 (en) | 2009-04-10 | 2013-11-28 | Ablynx Nv | Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| PH12022550313A1 (en) * | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP3466972B1 (en) | 2011-06-23 | 2026-03-04 | Ablynx NV | Serum albumin binding proteins |
| PH12014500380A1 (en) * | 2011-08-17 | 2022-05-02 | Glaxo Group Ltd | Modified proteins and peptides |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| NO2768984T3 (enExample) * | 2015-11-12 | 2018-06-09 | ||
| CN108699151B (zh) * | 2016-02-12 | 2022-08-12 | 埃博灵克斯股份有限公司 | 用于制备免疫球蛋白单可变结构域的方法 |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Pending
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en not_active Ceased
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active Active
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 CA CA3005085A patent/CA3005085C/en active Active
- 2016-11-14 SM SM20170590T patent/SMT201700590T1/it unknown
- 2016-11-14 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 MX MX2018005992A patent/MX385207B/es unknown
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/en unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
-
2018
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506839A5 (enExample) | ||
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| JP2020186248A5 (enExample) | ||
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2017519503A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2020536888A5 (enExample) | ||
| US11384141B2 (en) | Serum albumin binding antibodies for tuneable half-life extension of biologics | |
| JP2010536384A5 (enExample) | ||
| JP2011523550A5 (enExample) | ||
| CA3011786C (en) | ANTI-TUMOR NECROSIS FACTOR ALPHA ANTIBODIES AND FUNCTIONAL FRAGMENTS OF SAID ANTIBODIES | |
| AU2014227664A1 (en) | Dual specific binding proteins directed against TNFalpha | |
| JP2020500510A5 (enExample) | ||
| JP2017504321A5 (enExample) | ||
| CA3011784A1 (en) | Anti-tnf.alpha.-antibodies and functional fragments thereof | |
| CN104955846B (zh) | 人源化抗hmgb1抗体或其抗原结合性片段 | |
| JPWO2021116182A5 (enExample) | ||
| CN105189550A (zh) | 改善的tnf结合蛋白 | |
| JP7108956B2 (ja) | 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬 | |
| RU2022112308A (ru) | Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния | |
| HK1238660A1 (en) | Improved tnf binders | |
| HK1238660B (en) | Improved tnf binders |